Uciane Scarlett

Principal

2021 - Current

Principal

2019 - 2021

Life science investing, company creation, portfolio management Company Creation/Operations/Financing: T-Cypher Bio (interim Exec Chair), PepGen, ORFonyx, Alethiomics, Endlyz Boards: T-Cypher Bio, PepGen (NASDAQ: PEPG), Miro Bio (acq. by Gilead), Scenic Bio, DJS (acq. by AbbVie)

Associate | EIR

2018 - 2019

Life science investing, company creation, portfolio company operations. Company Creation/Board: Quench Bio, Dyne Therapeutics, Navitor Operations: Korro Bio, AVRO BIO, Quench, Dyne

Director of Business Development & Strategy

2016 - 2018

Drove business development & corporate/pipeline strategy; participated in venture financing; conceptualized strategic academic partnership; presented to BoD; engaged with various bankers, analysts, VCs

Manager | Consultant | Associate

2011 - 2016

Corporate/pipeline strategy, early commercial strategy, business development; strong oncology focus Drove internal initiatives geared towards growing Clarion's oncology business Published two articles (business journal & peer-reviewed journal) in oncology

Postdoctoral Fellow

2011 - 2011